EKSO Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -0.63%, SMA50 18.59%, SMA200 88.65%). The stock’s 14-day RSI is 52.04 (neutral), while the ATR of 1.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -24.51% below its high and over 267.03% above its low. Average 10-day trading volume of 457.57 thousand shares is significantly above the 3-month average of 160.21 thousand, indicating heightened recent market interest.

Ekso Bionics Holdings, Inc. has 2.61 million shares outstanding. The public float is 2.24 million shares, elevated short interest at 5.40% of float. This equals 138.49 thousand shares. The short ratio is 1.09 days. Institutional investors hold 2.89% of the float. Insiders own 4.95%. Angold Russ holds 391.33 thousand shares, SHERMAN STEVEN has 364.91 thousand shares and ASHER DANIEL has 270.43 thousand shares. Over the past six months, insider transactions show net buying. They sold 1.32 thousand shares across 1 transactions.

Ekso Bionics Holdings, Inc. generated EPS of -$5.06 over the past year. Five-year average earnings growth is 31.73%. Wall Street analysts project EPS growth of 80.74% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.50 to $6.00. The high target offers -57.21% upside. The low target suggests -72.97% downside. The mean target is $7.75. This offers -65.09% upside. Ekso Bionics Holdings, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended April 28, 2026, missed forecasts by 3300.0%. The prior quarter beat by 1850.0%. Over the last six quarters, Apple has recorded several small beats. These include 100.0% in March 03, 2025.

Ekso Bionics Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.61. This means the shares are trading above this model’s fair value.

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) closed at $22.20 USD, losing -$0.31 (-1.38%) from the previous close of $22.51. The stock is currently mid-range between its 52-week high and low $2.73 and $26.56. With a market capitalization of about $53.85 million, Ekso Bionics Holdings, Inc. is classified as a micro-cap and shows market-like volatility (beta ~0.82). Key stats such as the average daily volume over the past year has been around 78.94 thousand shares, trading with heavier-than-usual volume. Headquartered in San Rafael, CA, Ekso Bionics Holdings, Inc. operates in the Healthcare sector and the Medical - Equipment & Services industry. Led by CEO Scott G. Davis, the company employs approximately 53 people and listed since January 15, 2014. Ekso Bionics Holdings, Inc. designs, develops, distributes, and commercializes exoskeleton products in the Americas, Europe, the Middle East, Africa, the Asia Pacific, and internationally.

Ekso Bionics Holdings, Inc. trades at a P/E ratio of -4.12, slightly below the S&P 500 average, with a price-to-sales ratio of 4.66 and a price-to-book ratio of 13.78 reflecting a rich premium to book value. The P/FCF stands at -4.49, also below market averages. Compared to sector medians, Ekso Bionics Holdings, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) shares are flat -4.86% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Ekso Bionics Holdings, Inc. trading at a premium to the broader market with a P/E of -4.12. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $7.00, suggesting -68.51% downside. Our AI forecast model points to short-term strength (12.96% over two weeks), a medium-term rise (66.89% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Ekso Bionics Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 12.96%, with price expected at $25.11 by July 10, 2026, within a range of $23.48 to $26.82 3-Month Outlook: Projected rise of 66.89%, reaching $37.10 by September 24, 2026, with a range of $33.41 to $40.67. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by June 25, 2027, within a range of $0.00 to $0.00.